Top Industry News

Pfizer has initiated an additional $2.5-billion restructuring plan, expected to realize savings from 2027 through 2029. The company made the announcement as part of its second-quarter/first-half 2026 results announced this week (August 4, 2026).   Approximately $1.0 billion of the additional cuts will come from the company’s ongoing overall cost realignment program…

Gerresheimer has agreed to sell two of its packaging units—Centor US Holding, which specializes in packaging systems for dispensing prescription drugs, and its global primary packaging plastics business—to an affiliate of funds advised by Apax…

Johnson & Johnson (J&J) has announced that Jennifer Taubert, currently Executive Vice President and Worldwide Chairman of the company’s Innovative Medicine business segment will retire following a 21-year tenure with the company. She will be succeeded by Tom Cavanaugh, who currently serves as Group Chairman,…

The latest from CDMOs, CMOs, and suppliers featuring Piramal Pharma Solutions, Codis, Fujifilm Biotechnologies, Nuecell Bio and Altasciences.   Chemicals/Chemical API Manufacturing * Piramal Pharma Adds Spray-Drying Suite in Peptide API Facility Biologics Manufacturing * NueCell-Bio Launches as Cell…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Curium, Lantheus, Johnson & Johnson, BioNTech, Indivior and Supernus Pharma. Highlights below.   For the latest news roundup on…

The latest from small and Emerging Pharma companies featuring Braveheart Bio, Attovia Therapeutics, Latigo Biotherapeutics, Expedition Therapeutics and BlossomHill Therapeutics.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Braveheart Bio Files $383-M…

Bachem, a CDMO of peptide and oliogionucletides, has announced plans to build a large-scale production facility in Sisslerfeld (Eiken, Switzerland) as part of a strategic collaboration. The company plans to invest more than CHF 500…

GSK has initiated a three-year £1.9 billion ($2.5 billion) restructuring program, which it has dubbed as the “Accelerate Growth” program as part of a goal to align the company’s organization and cost base to…

Resilience, a CDMO of biologic drug substances and drug products, has expanded its strategic partnership with Eli Lilly and Company to increase US production with new manufacturing investments in Ohio.…

BeOne Medicines, a bio/pharmaceutical company focused on oncology, has announced a $300-million expansion of its clinical and commercial-stage manufacturing and research and development center in Hopewell, New Jersey, bringing the company’s total US…